AUPH: Riding the Market Waves of Growth and Decline in 2023

The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a gain of 125.35%.However, over the last six months, we can see a stronger performance of -13.93%. Over the last 30 days, the price of AUPH has fallen by 34.46%. And in the last five days, it has surged by 19.16%.

At present, Aurinia Pharmaceuticals Inc (AUPH) has a stock price of $9.73. In the previous session, the stock saw a rise, peaking at $9.395 after an opening price of $8.65. The day’s lowest price was $8.50, and it closed at $9.24.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Aurinia Pharmaceuticals Inc experienced a rather steady stock market performance. The highest value in the past year was recorded at $12.43 on 07/28/23 and the lowest value was $4.07 on 12/28/22.

52-week price history of AUPH Stock

Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Aurinia Pharmaceuticals Inc’s current trading price is -21.68% away from its 52-week high, while its distance from the 52-week low is 139.19%. The stock’s price range during this period has varied between$4.07 and $12.43. The Aurinia Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 3.5 million for the day, a figure considerably higher than their average daily volume of 1.73 million over last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Aurinia Pharmaceuticals Inc (AUPH) has experienced a quarterly rise of 4.90% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.40B and boasts a workforce of 300 employees.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 9.03, with a change in price of +0.17. Similarly, Aurinia Pharmaceuticals Inc recorded 2,009,965 in trading volume during the last 100 days, posting a change of +1.76%.

AUPH’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for AUPH stands at 0.24. Similarly, the long-term debt-to-equity ratio is also 0.20.

AUPH Stock Stochastic Average

Aurinia Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 93.57%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 93.57%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 94.13% and 88.03%, respectively.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts